L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.
@article{Warrington1989LhistidinolIT, title={L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.}, author={Robert C. Warrington and Wei D. Fang}, journal={British Journal of Cancer}, year={1989}, volume={60}, pages={652 - 656} }
DBA/2J mice bearing a clonal isolate of the transplantable murine lymphocytic leukaemia line P388 were used to examine the effects of L-histidinol on the antitumour activity of three alkalyating agents (bis-chloroethylnitrosourea (BCNU), cis-diamminedichloroplatinum (II) (cisDDP) and cyclophosphamide) and the antitumour antibiotic daunomycin. [] Key Result Single, combined treatments with L-histidinol and either BCNU or cisDDP, at doses of the alkylating agents which were ineffective when used alone, were…
11 Citations
L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.
- Biology, MedicineCancer research
- 1992
Therapeutic studies were conducted with L-histidinol, in combination with cyclophosphamide, bischloroethylnitrosourea, 5-fluorouracil, phenylalanine mustard, or cis-platinum(II)diammine dichloride,…
Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin
- BiologyInvestigational New Drugs
- 2007
It is suggested that EDSM has significant synergistic capabilities in both animal tumor models, but strong therapeutic enhancement of cisplatin efficacy is only seen when the tumor is sensitive to CDDP.
L-Histidinol Attenuates Fanconi Syndrome Induced by Ifosfamide in Rats
- Biology, MedicineNephron Experimental Nephrology
- 1999
Oral supplementation of LHL can partially protect against IFO-induced Fanconi syndrome (FS) induced by IFO in rats, with beneficial effects on renal dysfunction and nonprotein sufhydry depletion and lipid peroxide accumulation.
Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
- BiologyAnnals of oncology : official journal of the European Society for Medical Oncology
- 1994
A pilot scale clinical trial indicated the feasibility of antibody directed enzyme prodrug therapy (ADEPT), and the difference between prodrug and active drug creates the opportunity to degrade active drug selectively in blood and thus protect normal tissues.
R-2HMP: an Orally Active Agent Combining Independent Antiapoptotic and MAO-B-Inhibitory Activities
- Biology
- 2006
The present review will describe the development and known activity of the lead compound R-N-(2heptyl)-N-methylpropargylamine hydrochloride (R-2HMP) and at least one of the metabolites of this lead compound appears to be responsible for the antiapoptotic effect while being essentially devoid of MAO-B-inhibitory activity.
Strategies of Protection of Normal Cells During Chemo- and Radio-Therapy Based on Modulation of Cell Cycle and Apoptotic Pathways
- Biology, Chemistry
- 2005
The ultimate goal of cancer therapy is to selectively kill cancer cells, while sparing normal cells, and BCR-ABL, a product of a chromosomal translocation, is the most validated target in oncology.
PROPARGYLAMINE FOR ENHANCING CANCER THERAPY
- Biology, Medicine
- 2017
L-Histidinol in experimental che motherapy: improving the Selectivity and efficacy of anti cancer drugs, eliminating metastatic disease and revering the multi-drug resistant phenotype.
Inhibition of protein N-myristoylation: a therapeutic protocol in developing anticancer agents.
- Biology, ChemistryCurrent cancer drug targets
- 2012
The current review focuses on developments of various chemical NMT inhibitors with potential roles as anticancer agents.
References
SHOWING 1-10 OF 17 REFERENCES
Histidinol-mediated improvement in the specificity of 1-beta-D-arabinofuranosylcytosine and 5-fluorouracil in L 1210 leukemia-bearing mice.
- Biology, ChemistryCancer research
- 1984
It is reported here that histidinol confers substantial protection upon the bone marrow cells of DBA/2J mice from the drugs 1-beta-D-arabinofuranosylcytosine and 5-fluorouracil without diminishing the toxicities of these agents for in situ leukemia cells.
Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice.
- Biology, MedicineJournal of the National Cancer Institute
- 1987
Quantitative cell survival assays of murine bone marrow cells and of clonogenic tumor cells obtained from treated animals demonstrated that L-histidinol eliminated the bone marrow toxicity otherwise attending the use of the drugs ara-C and FUra.
Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors.
- Biology, ChemistryCancer research
- 1987
The results of these studies indicate that the administration of L-histidinol can protect the CD8F1 mouse from FUra-associated leukopenia, body weight loss, and ultimately, from mortality.
Specificity, schedule, and proliferation dependence of infused L-histidinol after 5-fluorouracil in mice.
- BiologyCancer research
- 1988
It is demonstrated that the FUra/L-histidinol combination indeed protects only normal cells but that the postulated proliferation dependence is absent, indicating an alternate biological mechanism.
A novel approach for improving the efficacy of experimental cancer chemotherapy using combinations of anticancer drugs and L-histidinol.
- Biology, ChemistryAnticancer research
- 1986
Results demonstrate that the L-histidinol/anticancer drug combination approach to chemotherapy is effective with a variety of clinically-relevant antineoplastic agents.
Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease.
- Biology, ChemistryJournal of the National Cancer Institute
- 1985
L-histidinol mediates a substantial increase in the specificities of ara-C and FUra in mice bearing an established bone marrow leukemic condition and increased significantly the toxicities of these agents for the intrafemoral tumor cells.
Reversal of the multidrug-resistant phenotype of Chinese hamster ovary cells by L-histidinol.
- Biology, ChemistryJournal of the National Cancer Institute
- 1989
The amino acid analogue L-histidinol reverses the multidrug-resistance (MDR) attribute of the colchicine-resistant (CHR) variant CHRC5, a Chinese hamster ovary cell line that overexpresses a plasma…
Effect of L
- 1988
Effect of Lhistidinol on the metabolism of 5-fluorouracil in the BALB/ c x DBA/8 Fl murine model system
- Cancer Res
- 1988
Effect of Lhistidinol on the metabolism of 5-fluorouracil in the BALB/ c x DBA/8 Fl murine model system
- Cancer Res
- 1988